Title:
NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/094185
Kind Code:
A1
Abstract:
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable salt, stereoisomer and deuterated product thereof, the definition of each group being as defined in the description. Studies have shown that the compound represented by general formula (A') or the pharmaceutically acceptable salt, stereoisomer and deuterated product thereof have high biological activity against an NLRP3 inflammasome, and have important clinical development value for the treatment of NLRP3-related diseases. Y-W-R3 (A')
Inventors:
LI LIN (CN)
WU FRANK (CN)
WU FRANK (CN)
Application Number:
PCT/CN2023/129677
Publication Date:
May 10, 2024
Filing Date:
November 03, 2023
Export Citation:
Assignee:
TRANSTHERA SCIENCES NANJING INC (CN)
International Classes:
C07D487/04; A61K31/502; A61K31/504; A61K31/53; A61P37/02; C07D237/26; C07D237/34; C07D401/12; C07D405/12; C07D409/12; C07D471/04; C07D495/04
Domestic Patent References:
| WO2023028536A1 | 2023-03-02 | |||
| WO2022216971A1 | 2022-10-13 | |||
| WO2023028534A1 | 2023-03-02 | |||
| WO2022238347A1 | 2022-11-17 | |||
| WO2022253936A1 | 2022-12-08 | |||
| WO2022166890A1 | 2022-08-11 | |||
| WO2022230912A1 | 2022-11-03 | |||
| WO2023066377A1 | 2023-04-27 | |||
| WO2023088856A1 | 2023-05-25 | |||
| WO2023088987A1 | 2023-05-25 | |||
| WO2023131277A1 | 2023-07-13 | |||
| WO2023186020A1 | 2023-10-05 |
Foreign References:
| CN107266419A | 2017-10-20 | |||
| CN113784957A | 2021-12-10 | |||
| CN115279739A | 2022-11-01 | |||
| CN115417856A | 2022-12-02 | |||
| CN116789674A | 2023-09-22 |
Attorney, Agent or Firm:
LINDA LIU & PARTNERS (CN)
Download PDF: